Cargando…

Low frequency of mismatch repair deficiency in gallbladder cancer

BACKGROUND: DNA mismatch repair (MMR) deficiency is a major pathway of genomic instability in cancer. It leads to the accumulation of numerous mutations predominantly at microsatellite sequences, a phenotype known as microsatellite instability (MSI). MSI tumors have a distinct clinical behavior and...

Descripción completa

Detalles Bibliográficos
Autores principales: Goeppert, Benjamin, Roessler, Stephanie, Renner, Marcus, Loeffler, Moritz, Singer, Stephan, Rausch, Melina, Albrecht, Thomas, Mehrabi, Arianeb, Vogel, Monika Nadja, Pathil, Anita, Czink, Elena, Köhler, Bruno, Springfeld, Christoph, Rupp, Christian, Weiss, Karl Heinz, Schirmacher, Peter, von Knebel Doeberitz, Magnus, Kloor, Matthias
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506936/
https://www.ncbi.nlm.nih.gov/pubmed/31068195
http://dx.doi.org/10.1186/s13000-019-0813-5
_version_ 1783416937661857792
author Goeppert, Benjamin
Roessler, Stephanie
Renner, Marcus
Loeffler, Moritz
Singer, Stephan
Rausch, Melina
Albrecht, Thomas
Mehrabi, Arianeb
Vogel, Monika Nadja
Pathil, Anita
Czink, Elena
Köhler, Bruno
Springfeld, Christoph
Rupp, Christian
Weiss, Karl Heinz
Schirmacher, Peter
von Knebel Doeberitz, Magnus
Kloor, Matthias
author_facet Goeppert, Benjamin
Roessler, Stephanie
Renner, Marcus
Loeffler, Moritz
Singer, Stephan
Rausch, Melina
Albrecht, Thomas
Mehrabi, Arianeb
Vogel, Monika Nadja
Pathil, Anita
Czink, Elena
Köhler, Bruno
Springfeld, Christoph
Rupp, Christian
Weiss, Karl Heinz
Schirmacher, Peter
von Knebel Doeberitz, Magnus
Kloor, Matthias
author_sort Goeppert, Benjamin
collection PubMed
description BACKGROUND: DNA mismatch repair (MMR) deficiency is a major pathway of genomic instability in cancer. It leads to the accumulation of numerous mutations predominantly at microsatellite sequences, a phenotype known as microsatellite instability (MSI). MSI tumors have a distinct clinical behavior and commonly respond well to immune checkpoint blockade, irrespective of their origin. Data about the prevalence of MSI among gallbladder cancer (GBC) have been conflicting. We here analyzed a well-characterized cohort of 69 Western-world GBCs. METHODS: We analyzed the mononucleotide MSI marker panel consisting of BAT25, BAT26, and CAT25 to determine the prevalence of MMR deficiency-induced MSI. RESULTS: MSI was detected in 1/69 (1.4%) of analyzed GBCs. The detected MSI GBC had a classical histomorphology, i.e. of acinar/tubular/glandular pancreatobiliary phenotype, and showed nuclear expression of all four MMR proteins MLH1, MSH2, MSH6, and PMS2. The MSI GBC patient showed a prolonged overall survival, despite having a high tumor stage at diagnosis. The patient had no known background or family history indicative of Lynch syndrome. CONCLUSIONS: Even though the overall number of MSI tumors is low in GBC, the potentially therapeutic benefit of checkpoint blockade in the respective patients may justify MSI analysis of GBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13000-019-0813-5) contains supplementary material, which is available to authorized users.
format Online
Article
Text
id pubmed-6506936
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-65069362019-05-13 Low frequency of mismatch repair deficiency in gallbladder cancer Goeppert, Benjamin Roessler, Stephanie Renner, Marcus Loeffler, Moritz Singer, Stephan Rausch, Melina Albrecht, Thomas Mehrabi, Arianeb Vogel, Monika Nadja Pathil, Anita Czink, Elena Köhler, Bruno Springfeld, Christoph Rupp, Christian Weiss, Karl Heinz Schirmacher, Peter von Knebel Doeberitz, Magnus Kloor, Matthias Diagn Pathol Research BACKGROUND: DNA mismatch repair (MMR) deficiency is a major pathway of genomic instability in cancer. It leads to the accumulation of numerous mutations predominantly at microsatellite sequences, a phenotype known as microsatellite instability (MSI). MSI tumors have a distinct clinical behavior and commonly respond well to immune checkpoint blockade, irrespective of their origin. Data about the prevalence of MSI among gallbladder cancer (GBC) have been conflicting. We here analyzed a well-characterized cohort of 69 Western-world GBCs. METHODS: We analyzed the mononucleotide MSI marker panel consisting of BAT25, BAT26, and CAT25 to determine the prevalence of MMR deficiency-induced MSI. RESULTS: MSI was detected in 1/69 (1.4%) of analyzed GBCs. The detected MSI GBC had a classical histomorphology, i.e. of acinar/tubular/glandular pancreatobiliary phenotype, and showed nuclear expression of all four MMR proteins MLH1, MSH2, MSH6, and PMS2. The MSI GBC patient showed a prolonged overall survival, despite having a high tumor stage at diagnosis. The patient had no known background or family history indicative of Lynch syndrome. CONCLUSIONS: Even though the overall number of MSI tumors is low in GBC, the potentially therapeutic benefit of checkpoint blockade in the respective patients may justify MSI analysis of GBC. ELECTRONIC SUPPLEMENTARY MATERIAL: The online version of this article (10.1186/s13000-019-0813-5) contains supplementary material, which is available to authorized users. BioMed Central 2019-05-08 /pmc/articles/PMC6506936/ /pubmed/31068195 http://dx.doi.org/10.1186/s13000-019-0813-5 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research
Goeppert, Benjamin
Roessler, Stephanie
Renner, Marcus
Loeffler, Moritz
Singer, Stephan
Rausch, Melina
Albrecht, Thomas
Mehrabi, Arianeb
Vogel, Monika Nadja
Pathil, Anita
Czink, Elena
Köhler, Bruno
Springfeld, Christoph
Rupp, Christian
Weiss, Karl Heinz
Schirmacher, Peter
von Knebel Doeberitz, Magnus
Kloor, Matthias
Low frequency of mismatch repair deficiency in gallbladder cancer
title Low frequency of mismatch repair deficiency in gallbladder cancer
title_full Low frequency of mismatch repair deficiency in gallbladder cancer
title_fullStr Low frequency of mismatch repair deficiency in gallbladder cancer
title_full_unstemmed Low frequency of mismatch repair deficiency in gallbladder cancer
title_short Low frequency of mismatch repair deficiency in gallbladder cancer
title_sort low frequency of mismatch repair deficiency in gallbladder cancer
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6506936/
https://www.ncbi.nlm.nih.gov/pubmed/31068195
http://dx.doi.org/10.1186/s13000-019-0813-5
work_keys_str_mv AT goeppertbenjamin lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT roesslerstephanie lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT rennermarcus lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT loefflermoritz lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT singerstephan lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT rauschmelina lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT albrechtthomas lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT mehrabiarianeb lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT vogelmonikanadja lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT pathilanita lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT czinkelena lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT kohlerbruno lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT springfeldchristoph lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT ruppchristian lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT weisskarlheinz lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT schirmacherpeter lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT vonknebeldoeberitzmagnus lowfrequencyofmismatchrepairdeficiencyingallbladdercancer
AT kloormatthias lowfrequencyofmismatchrepairdeficiencyingallbladdercancer